Army veteran Lt. Col. James Carafano (ret.) discusses the state of the Russia-Ukraine war and whether the U.S. will walk away ...

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer ...

We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, we are going to take a look at where Eli Lilly and Company (NYSE ...

Eli Lilly LLY underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Eli Lilly (Symbol: LLY) entered into oversold territory, hitting an RSI reading of 29.5 ...

Westover's track and auxiliary gym is getting a new name. The Cumberland County Board of Education has approved naming Westover High School's gym the "George Stackhouse Auxiliary Gymnasium" in a ...

Shares of AstraZeneca (AZN), Pfizer (PFE), Eli Lilly (LLY), Novo Nordisk (NVO), Johnson & Johnson (JNJ), GSK (GSK), and Sanofi (SNY) all declined. Gold futures climbed and the yield on the 10-year ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock is, again, testing multiyear lows. The $700 billion pharmaceutical giant ...